Telomerase expression in clinically non-functioning pituitary adenomas
- PDF / 841,260 Bytes
- 8 Pages / 595.276 x 790.866 pts Page_size
- 27 Downloads / 182 Views
ORIGINAL ARTICLE
Telomerase expression in clinically non-functioning pituitary adenomas Liana Lumi Ogino1 Elisa Baranski Lamback 2 Alexandro Guterres1 Carlos Henrique de Azeredo Lima1 Daniel Gomes Henriques2 Monique Alvares Barbosa3 Débora Aparecida Silva1 Aline Helen da Silva Camacho1,4 Leila Chimelli1 Leandro Kasuki2,5,6 Mônica R. Gadelha1,2,5 ●
●
●
●
●
●
●
●
●
●
1234567890();,:
1234567890();,:
Received: 21 August 2020 / Accepted: 10 October 2020 © Springer Science+Business Media, LLC, part of Springer Nature 2020
Abstract Purpose Non-functioning pituitary adenomas (NFPA) are benign tumors, however, some are agressive. We aimed to assess if human telomerase reverse transcriptase (hTERT) is present in NFPA and if it can be used as a marker of aggressiveness and proliferation. Methods Consecutive patients operated for NFPA whose fresh frozen tumors were available were included. We analyzed tumor’s aggressiveness (based on radiological progression) and proliferation (based on Ki-67), as well as hTERT mRNA by quantitative real-time polymerase chain reaction (RT-qPCR). Results We included 109 samples from 86 patients followed for a median period of 60 months (5–120 months). Aggressive tumors were present in 66% cases and proliferative tumors in 47.7%. Seven (6.4%) samples expressed hTERT: 3 (42.8%) had aggressive and proliferative tumors, 2 (28.6%) only exhibited aggressiveness and the remaining 2 (28.6%) only proliferation. From the aggressive and proliferative tumors, 14% and 16%, respectively, expressed hTERT. From the nonaggressive and non-proliferative tumors, 9% and 6%, respectively, expressed hTERT. Conclusion hTERT expression is present in a minority of NFPA and does not seem to be related to aggressiveness or proliferation in NFPA. Keywords Non-functioning pituitary adenomas Telomerase Tumorigenesis Pituitary tumor ●
●
●
Introduction
* Mônica R. Gadelha [email protected] 1
Neuropathology and Molecular Genetics Laboratory – Instituto Estadual do Cérebro Paulo Niemeyer, Rio de Janeiro, Brazil
2
Neuroendocrinology Research Center/ Endocrinology Division – Medical School and Hospital Universitário Clementino Fraga Filho – Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil
3
Radiology Division – Instituto Estadual do Cérebro Paulo Niemeyer, Rio de Janeiro, Brazil
4
Pathology Division – Instituto Nacional do Câncer, Rio de Janeiro, Brazil
5
Neuroendocrinology Division – Instituto Estadual do Cérebro Paulo Niemeyer, Rio de Janeiro, Brazil
6
Endocrinology Division – Hospital Federal de Bonsucesso, Rio de Janeiro, Brazil
Pituitary adenomas correspond to up to 15% of intracranial neoplasms [1]. They are divided according to their hormonal activity in functioning or non-functioning, and to their size in microadenomas (
Data Loading...
